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Abstract
Background: Specificity protein (Sp) transcription factors play pivotal roles in maintaining the phenotypes of many
cancers. We hypothesized that the antineoplastic effects of sulindac and its metabolites were due, in part, to
targeting downregulation of Sp transcription factors.
Methods: The functional effects of sulindac, sulindac sulfone and sulindac sulfide on colon cancer cell proliferation
were determined by cell counting. Effects of these compounds on expression of Sp1, Sp3, Sp4 and pro-oncogenic
Sp-regulated genes were determined by western blot analysis of whole cell lysates and in transient transfection
assays using GC-rich constructs.
Results: Sulindac and its metabolites inhibited RKO and SW480 colon cancer cell growth and the order of growth
inhibitory potency was sulindac sulfide > > sulindac sulfone > sulindac. Treatment of SW480 and RKO cells with
sulindac sulfide downregulated expression of Sp1, Sp3 and Sp4 proteins. Sulindac sulfide also decreased expression
of several Sp-regulated genes that are critical for cancer cell survival, proliferation and angiogenesis and these
include survivin, bcl-2, epidermal growth factor receptor (EGFR), cyclin D1, p65 subunit of NFκB and vascular
endothelial growth factor (VEGF). Sulindac sulfide also induced reactive oxygen species (ROS) and decreased the
level of microRNA-27a in colon cancer cells, which resulted in the upregulation of the Sp-repressor ZBTB10 and
this resulted in downregulation of Sp proteins.
Conclusions: The results suggest that the cancer chemotherapeutic effects of sulindac in colon cancer cells are
due, in part, to its metabolite sulindac sulfide which downregulates Sp transcription factors and Sp-regulated
pro-oncogenic gene products.
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Background
Nonsteroidal anti-inflammatory drugs (NSAIDs) and
cyclooxygenase (COX) inhibitors are widely used as
analgesics and treatment of diseases associated with an
inflammatory response, such as arthritis and cardiovas-
cular diseases. Cancer has been associated with inflam-
mation and there is epidemiologic evidence that
NSAIDs decrease the risk for development of several
cancers [1–3]. Several studies show that the use of as-
pirin and other NSAIDs is associated with decreased
incidence of colon cancer, and aspirin use and treat-
ment is also associated with a decrease in colon polyp
formation [4–6]. Aspirin and NSAIDs such as sulindac
decrease colon polyp formation and the latter com-
pound has been used in several clinical studies for in-
hibition of polyp formation in colon cancer patients
and genetically susceptible individuals [7–9].
Sulindac, a COX-1 and COX-2 inhibitor, has been ex-
tensively investigated as a potent chemotherapeutic drug
for treatment of colon and other cancers; however, due
to the metabolism of sulindac (sulfoxide) to its sulfone
(oxidation) or sulfide (reduction) metabolites, the mech-
anisms of action and identity of the active compound(s)
are uncertain. Several reports show that sulindac and its
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metabolites exhibit pronounced pro-apoptotic activity in
cancer cell lines and animal models and this includes
activation of both extrinsic and intrinsic apoptosis path-
ways [10–17]. For example, sulindac induced apoptosis
in HT-29 colon cancer cells and this is related to down-
regulation of survivin which in turn is due to decreased
expression of β-catenin which regulates survivin expres-
sion through the transcription factor TCF-4 [13]. Other
studies also show downregulation of β-catenin and/or
survivin in cancer cells and tumors treated with sulindac
or its metabolites [15–17] and the pro-apoptotic effect
of survivin downregulation in head and neck sarcoma
and carcinoma cells is STAT2-dependent [11, 12].
In addition, it has also been reported that sulindac and
its metabolites exhibit growth inhibitory activity and this
is associated, in part, not only with downregulation of
survivin but also decreased expression of the epidermal
growth factor receptor (EGFR) and vascular endothelial
growth factor (VEGF) [18–21]. Studies in this laboratory
have demonstrated that basal expression of genes, such
as survivin, VEGF and EGFR, in various cancer cell lines
is dependent on specificity protein (Sp) transcription
factors Sp1, Sp3 and Sp4 [22–26] which are highly
expressed in many cancer cells and tumors [27]. In this
study, we initially compared the growth inhibitory effects
of sulindac and its metabolites in SW480 and RKO
colon cancer cells and their order of activity was sulin-
dac sulfide > sulindac sulfone > sulindac after treatment
for 24, 48 or 72 h. At concentrations of sulindac and its
metabolites that inhibited cell growth, we observed that
only sulindac sulfide decreased levels of Sp1, Sp3 and
Sp4 proteins and this was accompanied by decreased ex-
pression of Sp1-dependent genes such as VEGF, survivin,
EGFR and bcl-2. Mechanistic studies suggest that sulin-
dac sulfide induces reactive oxygen species (ROS) which
in turn downregulates expression of Sp1, Sp3 and Sp4 in
colon cancer cells [27].
Methods
Cell lines and cell culture, chemicals, oligonucleotides,
plasmids and antibodies
SW480 and RKO colon cancer cell lines were obtained
from the American Type Culture Collection (ATCC,
Manassas, VA) and maintained in Dulbecco’s modified
Eagle’s medium (DMEM) nutrient mixture with Ham’s
F-12 (DMEM/Ham’s F-12) (Sigma-Aldrich, St. Louis,
MO) as described [25]. Sulindac, sulindac sulfone and
sulindac sulfide were purchased from LKT Laboratories
(St. Paul, MN). Real-time PCR primer sequences for
ZBTB10 are forward: 5'-GCT GGA TAG TAG TTA
TGT TGC and reverse: 5'-CTG AGT GGT TTG ATG
GAC AGA.
Sp1 construct (pSp1-Luc) contains the −751 to −20 bp
promoter insert linked to a luciferase reporter gene [28]
and Sp3 construct (pSp3-Luc) contains the −417 to
−38 bp promoter insert [29]. Survivin construct (pSurvi-
vin-Luc) contains the −220 to +49 bp promoter insert [30]
and VEGF construct (pVEGF-Luc) contains the −2018 to
+50 bp promoter insert [31] and miR-27a construct
(pmiR-27a-Luc) contains the −603 to +36 bp promoter in-
sert [32]. The empty luciferase vector pGL2 was also used
in parallel as a negative control in luciferase assay. Sp1,
survivin, cleaved PARP and β-actin antibodies were pur-
chased from Upstate/Millipore (Lake Placid, NY), R&D
Systems (Minneapolis, MN), Cell Signaling Technology
(Beverly, MA) and Sigma-Aldrich, respectively. Sp3, Sp4,
EGFR, p65 and VEGF antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA).
Cell proliferation assay
Cells were plated in 12-well plates (3 × 104 per well) and
allowed to attach for 24 h. Cells were then treated with
solvent control (DMSO) or varying concentrations of
compounds and then trypsinized and counted after 24,
48 and 72 h using a Coulter Z1 particle counter.
Western blot analysis
Cells were plated in 6-well plates (3 × 105 per well),
allowed to attach for 24 h, and then treated with DMSO
or varying concentrations of indicated compounds. Cells
were lysed after 24 and 48 h and whole cell lysates were
resolved on 7.5 or 12 % SDS-PAGE gels and proteins
were transferred onto polyvinylidene difluoride mem-
branes by wet electroblotting. Membranes were probed
for indicated proteins by antibodies and β-actin was used
as a loading control.
Flow cytometry
Cells were treated with 100 μM sulindac sulfide for indi-
cated time and the general oxidative stress indicator
CM-H2DCFDA (Invitrogen/Life Technologies, Waltham,
MA) was used according to the manufacturer’s protocol.
Fluorescence was measured by BD Accuri C6 flow cyt-
ometer (BD Biosciences, San Jose, CA) and data were
analyzed according to the manufacturer’s guide.
Transfection and luciferase assay
Cells were plated in 12-well plates (1.5 × 105 per well),
allowed to attach for 24 h, and 400 ng of luciferase con-
struct (pSp1, pSp3, pSurvivin, pVEGF or pMir27a-Luc)
and 40 ng of β-galactosidase constructs (β-gal) with a
constitutively active promoter were cotransfected into
each well by Lipofectamine 2000 reagent (Invitrogen)
and analyzed essentially as described [26].
Quantitative real-time PCR and TaqMan assay
Cells were treated as indicated and total RNA was ex-
tracted using RNeasy kit (Qiagen, Valencia, CA) then
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reverse transcribed using SuperScript reverse tran-
scriptase (Invitrogen). Real-time PCR was carried out
using a SYBR Green method (Applied Biosystems,
Foster City, CA), and messenger RNA (mRNA) levels
of target genes were normalized to that of the TATA-
binding protein (TBP, as internal control). Total miRNA
was extracted using mirVana isolation kit (Ambion/Life
Technologies, Grand Island, NY) and TaqMan probes for
miR-27a were purchased from the same company. Taq-
Man assay and analysis were carried out according to the
manufacturer’s protocol.
Statistical analysis
Statistical significance of differences between experiment
groups in cell proliferation, luciferase, flow cytometry,
real-time PCR and TaqMan assays was analyzed using
unpaired Student’s t-test and P value of <0.05 was con-
sidered statistically significant. Experiments were done
in triplicate and all results are expressed as mean ±
standard deviation (S.D.) for at least three independent
determinations for each group.
Results
Results illustrated in Fig. 1a and b show that sulindac
and sulindac sulfone inhibited growth of SW480 and
RKO cells at cytostatic concentrations between 600–900
and 225–300 μM, respectively. Western blot analysis of
whole cell lysates from these cells indicated that 600 to
1200 μM concentrations of sulindac did not affect ex-
pression of Sp1, Sp3 and Sp4 proteins in SW480 and
RKO cells after treatment for 24 and 48 h (Fig. 1c). Simi-
lar results were observed in these cells after treatment
with 225 or 300 μM sulindac sulfone for 24 and 48 h
(Fig. 1d) suggesting that growth inhibitory effects of
these compounds was Sp-independent. Treatment of
SW480 and RKO cells with 50 or 75 μM sulindac sulfide
for 24 h inhibited cell proliferation (Fig. 2a and b) and
also slightly decreased expression of Sp1, Sp3 and Sp4
proteins in SW480 and RKO cells (Fig. 2c and d). Sulindac
sulfide induced similar responses after treatment for 48 h;
however, at this time point, there was a pronounced
downregulation of Sp1, Sp3 and Sp4 proteins in SW480
(Fig. 2c) and RKO (Fig. 2d) cells. Thus, sulindac sulfide
was the most active sulindac derivative as observed in pre-
vious studies [33, 34] and the results suggest that the
growth inhibitory effects of sulindac sulfide are correlated
with downregulation of pro-oncogenic Sp proteins, and
previous studies show that knockdown of one or more
[35, 36] Sp proteins in colon cancer cells decreases cell
cycle progression and induces apoptosis.
We also investigated the effects of sulindac sulfide on
Sp-dependent pro-apoptotic, growth inhibitory and
anti-angiogenic responses in colon cancer cells. Results
illustrated in Figs. 3a and b show that sulindac sulfide
decreased EGFR expression in SW480 and RKO cells after
treatment for 24 and 48 h and this is consistent with a de-
crease of EGFR mRNA (qPCR data not shown). We also
examined the effects of sulindac sulfide on the p65 sub-
unit of NFκB which is an Sp-dependent gene product in
some cancer cell lines [26, 35, 37] and sulindac sulfide also
decreased p65 expression in SW480 and RKO cells
(Figs. 3a and b). In addition, sulindac sulfide also de-
creased expression of NFκB subunit p105 and upregulated
expression of the NFκB inhibitor IκBα in SW480 and
RKO cells (qPCR data not shown). Thus, sulindac sulfide-
induced inhibition of SW480 and RKO cell proliferation
was accompanied by downregulation of Sp1, Sp3, Sp4 and
the Sp-dependent gene products, EGFR and p65. Treat-
ment of SW480 cells with sulindac sulfide also decreased
survivin expression and this was accompanied by caspase-
dependent PARP cleavage which was observed after treat-
ment for 24 and 48 h (Fig. 3c). Similar results were ob-
served in RKO cells (Fig. 3d) and western blot data are in
agreement with decrease of survivin transcript observed
by qPCR (data not shown). It should be pointed out that
the pro-apoptotic concentrations of sulindac sulfide were
25–50 μM in both cell lines with effective concentrations
decreasing with increasing treatment times which is simi-
lar to that observed for sulindac sulfide-dependent down-
regulation of Sp1, Sp3 and Sp4. In addition, sulindac
sulfide also decreased expression of the Sp-dependent an-
giogenic VEGF gene product in SW480 (Fig. 3c) and RKO
(Fig. 3d) cells, demonstrating that sulindac sulfide-
dependent downregulation of Sp1, Sp3 and Sp4 is accom-
panied by decreased expression of Sp-dependent growth
promoting (EGFR), inflammatory (p65), survival (survivin)
and angiogenic (VEGF) gene products. We also observed
that knockdown of Sp1 by RNA interference inhibited
RKO and SW480 cell growth by >60 % (data not shown)
and this was consistent with previous reports showing that
knockdown of Sp1 in these same cell lines resulted in a
G0/G1 block in the cell cycle progression [36].
We also examined the effects of sulindac sulfide on
luciferase activity in cells transfected with reporter
constructs containing GC-rich sequences from the
Sp1 (pSp1-Luc) and Sp3 (pSp3-Luc) gene promoters
[28, 29]. Sulindac sulfide decreased luciferase activity
in both cell lines (Fig. 4a). Similar results were ob-
served in cells transfected with the GC-rich survivin
(pSurvivin-Luc) and VEGF (pVEGF-Luc) promoter-
luciferase constructs [30, 31] (Fig. 4b), demonstrating that
sulindac sulfide also decreased expression of Sp-regulated
genes with GC-rich promoters. These results suggest a
mechanism that involves transcriptional repression of
GC-box-driven genes through sulindac sulfide-induced Sp
downregulation.
Several compounds including betulinic acid, tolfe-
namic acid and curcumin induce proteasome-dependent
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degradation of Sp proteins in prostate, pancreatic and
bladder cancer cells respectively [22, 23, 38, 39]; how-
ever, proteasome inhibitors did not block downregula-
tion of Sp1, Sp3 or Sp4 by sulindac sulfide in SW480
and RKO cells (data not shown). Recent studies have
identified a role for ROS in mediating repression of Sp
proteins and the nitro-NSAID GT-094 and curcumin
induce ROS-dependent downregulation of Sp proteins
and Sp-regulated gene products in colon cancer cells
[25, 40]. Results illustrated in Fig. 5a show by flow cy-
tometry that sulindac sulfide induced a time-dependent
increase in ROS in SW480 and RKO cells. Figure 5b
shows that sulindac sulfide downregulated Sp1, Sp3 and
Sp4 proteins and this was partially reversed in SW480
cells cotreated with sulindac sulfide plus the antioxidant
dithiothreitol (DTT). The other thiol antioxidants gluta-
thione (GSH) and N-acetylcysteine (NAC) were less active
than DTT as inhibitors of Sp downregulation in SW480
Fig. 1 Sulindac and sulindac sulfone inhibit colon cancer cell growth without decreasing expression of Sp1, Sp3 and Sp4 proteins. a, b Sulindac
and sulindac sulfone inhibit SW480 and RKO cell proliferation. Cells were treated with solvent control (DMSO), 600 or 900 μM sulindac, or 225 or
300 μM sulindac sulfone for 24, 48 and 72 h. Cell numbers were determined as described under Materials and Methods. Experiments were done
in triplicate and results are expressed as mean ± S.D. for each determination. c, d Sulindac and sulindac sulfone have no effect on expression of
Sp proteins in SW480 and RKO cells. Cells were treated with DMSO, 600 or 1200 μM sulindac, or 225 or 300 μM sulindac sulfone for 24 and 48 h.
Sp1, Sp3 and Sp4 cellular levels were determined by Western blot analysis as described under Materials and Methods and β-actin was used as
loading control
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cells. However, in parallel experiments in RKO cells
(Fig. 5c), DTT, GSH and NAC exhibited comparable ac-
tivity as inhibitors of sulindac sulfide-induced downreg-
ulation of Sp1, Sp3 and Sp4 and the thiol antioxidants
also inhibited the effects of sulindac sulfide on VEGF, bcl-
2 and survivin proteins in SW480 (Fig. 5d) and RKO
(Fig. 5e) cells. In contrast, expression of pro-apoptotic
protein Bax was decreased by sulindac sulfide (and
reversed by antioxidants) in SW480 cells (Fig. 5d) but not
in RKO cells (Fig. 5e). These results indicate that the effect
of sulindac sulfide on Bax is cell context-dependent. In
contrast, thiol antioxidants did not block the effects of
sulindac sulfide on cyclin D1, suggesting cyclin D1 is regu-
lated in an ROS/Sp-independent manner in SW480 and
RKO cells. Previous studies with ROS inducers suggest
that the mechanism of Sp downregulation is associated
Fig. 2 Sulindac sulfide inhibits colon cancer cell growth and decreases expression of Sp1, Sp3 and Sp4 proteins. a, c Sulindac sulfide inhibits SW480
and RKO cell proliferation. Cells were treated with DMSO, 25, 50, and 75 μM sulindac sulfide for 24 and 48 h. Cell numbers were determined as
described under Materials and Methods. Experiments were done in triplicate and results are expressed as percentage of control (mean ± S.D.).
b, d Sulindac sulfide decreases expression of Sp1, Sp3 and Sp4 proteins in SW480 and RKO cells. Cells were treated with DMSO, 25, 50, 75 and
100 μM sulindac sulfide for 24 and 48 h. Sp1, Sp3 and Sp4 cellular levels were determined by Western blot analysis as described under
Materials and Methods and β-actin was used as loading control
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with ROS-dependent repression of microRNA-27a (miR-
27a) which results in the induction of the Sp repressor
ZBTB10 [25, 40–42]. Treatment of SW480 and RKO cells
with sulindac sulfide decreased both miR-27a promoter
activity (Fig. 6a) and cellular level of miR-27a and this re-
sponse was attenuated after cotreatment with antioxidant
NAC (Fig. 6b). In a parallel experiment we observed that
sulindac sulfide induced miR-27a-targeted ZBTB10 gene
expression in SW480 and RKO cells (Fig. 6c). These re-
sults are consistent with previous studies in colon cancer
cells showing that the miR-27a antagomir and ZBTB10
overexpression decrease expression of Sp1, Sp3 and Sp4
in RKO and SW480 cells [36]. Thus, like other ROS-
inducing anticancer agents [25, 40–42], sulindac sulfide
disrupts the miR-27a:ZBTB10 axis and the transcriptional
repressor ZBTB10 competitively binds GC-rich cis-elem-
ent to decrease expression of Sp1, Sp3, Sp4 and Sp-
regulated genes (Fig. 6d).
Discussion
Sp transcription factors Sp1, Sp3 and Sp4 are highly
expressed in cancer cells/tumors and Sp1 is a negative
prognostic factor for survival of gastric and pancreatic
cancer and glioma patients [43–45]. Although Sp1 and
other Sp proteins are important for early embryonic
and postnatal development in mice, their expression is
relatively low in adult tissues and there is evidence that
Sp1 expression decreases with age in rodents and
humans [46–48]. The functional importance of Sp1,
Sp3 and Sp4 in cancer cells has been confirmed by
RNA interference (RNAi) showing that knockdown of
Sp transcription factors Sp1, Sp3 and Sp4 (singly or
combined) decreases cell proliferation, survival, angio-
genesis and inflammation [26, 35, 36, 42]. These results
are consistent with identification (by RNAi) of several
pro-oncogenic Sp-regulated genes important for cell
growth (cyclin D1, EGFR, c-Met), survival (bcl-2, survivin),
Fig. 3 Sulindac sulfide decreases expression of EGFR, p65, VEGF and survivin and induces PARP cleavage in colon cancer cells. a, b Sulindac
sulfide decreases expression of EGFR and the p65 subunit of NFκB in SW480 and RKO cells. Cells were treated with DMSO, 25, 50, 75 and 100 μM
sulindac sulfide for 24 and 48 h. EGFR and p65 cellular levels were determined by Western blot analysis as described under Materials and Methods and
β-actin was used as loading control. c, d Sulindac sulfide decreases expression of VEGF and survivin and induces PARP cleavage in SW480 and RKO
cells. Cells were treated with DMSO, 25, 50, 75 and 100 μM sulindac sulfide for 24 and 48 h. VEGF, survivin and cleaved PARP cellular levels
were determined by Western blot analysis as described under Materials and Methods and β-actin was used as loading control
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angiogenesis (VEGF and VEGF receptors), and inflam-
mation (p65 subunit of NFκB) [22, 23, 26, 41, 42].
Thus, Sp transcription factors clearly contribute to the
transformed cell phenotype and represent an example
of non-oncogene addiction by cancer cells. Studies in
this laboratory show that several structurally-diverse
anticancer drugs downregulate Sp transcription factors
through two major pathways, namely, degradation (activa-
tion of proteasomes or caspases) or by ROS-dependent
transcriptional repression (Fig. 6d) and activation of one
or both pathways is dependent on the agent and cell con-
text. For example, previous studies with NSAIDs show
that tolfenamic acid induced proteasome-dependent
degradation of Sp proteins in pancreatic cancer [38],
the nitro-NSAID GT-094 induced ROS-dependent re-
pression [25], and aspirin induced caspase-dependent
degradation of Sp1, Sp3 and Sp4 in colon cancer cells
and in a mouse xenograft [35].
In this study, we also observed that sulindac and its
metabolites inhibited proliferation of SW480 and RKO
colon cancer cells and sulindac sulfide was the most
active compound (Figs. 1a, b, 2a and c) and this was
consistent with their relatively potent growth-inhibitory
effects observed in other studies [29, 30]. At concentra-
tions of sulindac or sulindac sulfone that inhibited
SW480 and RKO cell proliferation, the levels of Sp1, Sp3
or Sp4 proteins were unchanged (Fig. 1c and d), whereas
sulindac sulfide-dependent growth inhibition was ac-
companied by decreased expression of Sp1, Sp3 and Sp4
(Fig. 2b and d). These results clearly distinguish between
sulindac sulfide and sulindac/sulindac sulfone and indicate
that the anticancer activity of sulindac sulfide may be due,
in part, to downregulation of Sp transcription factors.
Like tolfenamic acid and other compounds that in-
duce Sp downregulation, sulindac sulfide also decreased
expression of EGFR, survivin, VEGF and bcl-2 and also
decreased the p65 subunit of NFκB which is Sp-
regulated in only some cancer cell lines [26, 35, 37],
and a previous study showed that high doses of sulin-
dac also decreased survivin expression [49]. Tolfenamic
acid induces proteasome-dependent downregulation of
Sp1, Sp3 and Sp4 in pancreatic cancer cells [38]. However,
proteasome inhibitors did not block sulindac sulfide-
mediated repression of these transcription factors.
Studies with several ROS-inducing anticancer agents
show that ROS-dependent transcriptional repression of
Sp1, Sp3 and Sp4 (and Sp-regulated genes) is due to
downregulation of miR-27a and/or miR-20a/17-5p [25,
40–42]. Decreased expression of these microRNAs results
in induction of miR-targeted ZBTB10 and/or ZBTB4,
which have been characterized as “Sp-repressors” that
competitively displace Sp transcription factors from GC-
rich promoter sites to decrease gene expression (Fig. 6d).
In addition, similar results were observed in two cell lines
(RKO and SW480) that have distinct genetic backgrounds,
and previous studies in these cells with other agents that
target Sp transcription factors also resulted in down-
regulation of Sp proteins [25, 35, 36, 40]. In addition,
pharmacologic doses of ascorbate (which induces H2O2), t-
butylhydroperoxide and H2O2 also decreased expression of
Sp1, Sp3, Sp4 and Sp-regulated gene products in cancer cell
lines [26, 50], and a number of other ROS-inducing agents
including piperlongumine phenethylisothiocyanate and
benzylisothiocyanate also downregulate Sp proteins [42].
In this study, sulindac sulfide was observed to induce
ROS in SW480 and RKO cells in a time-dependent man-
ner in flow cytometry experiments using an ROS indica-
tor (Fig. 5). Results of our studies with sulindac sulfide
are consistent with the ROS-dependent gene repression
pathway where induction of ROS disrupts miR-27a-
Fig. 4 Sulindac sulfide decreases promoter gene activity of Sp1, Sp3,
survivin and VEGF in colon cancer cells. a Cells were transfected
with promoter-luciferase reporter constructs containing −751 bp
promoter sequence of SP1 gene (pSp1-Luc) or −417 bp of SP3 gene
(pSp3-Luc). b Cells were transfected with constructs containing
−269 bp of BIRC5 gene (pSurvivin-Luc) or −2018 bp of VEGFA gene
(pVEGF-Luc). After 6 h of transfection, cells were treated with DMSO,
25, 50 and 100 μM sulindac sulfide for 13 h. Luciferase activity was
determined as described under Materials and Methods. Experiments
were done in triplicate and results are expressed as fold of control
(mean ± S.D.). Asterisk (*) indicates statistical difference between
control (DMSO) and treatment (P < 0.05)
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ZBTB10 interaction to decrease miR-27a and induce
ZBTB10 (Fig. 6). ZBTB10 overexpression or miR-27a
antagonism also decreases Sp protein expression [36, 51]
and this is also consistent with sulindac sulfide-induced
downregulation of Sp1, Sp3, Sp4 and Sp-regulated genes
(Figs. 2 and 3).
Conclusions
This study demonstrates that sulindac sulfide, the active
metabolite of sulindac which is known to exhibit anti-
neoplastic activity in human and experimental models of
colon cancer, also downregulates Sp1, Sp3, Sp4 and pro-
oncogenic Sp-regulated genes in colon cancer cells. The
Fig. 5 Sulindac induces ROS in colon cancer cells and reversal of sulindac sulfide-induced gene downregulation by thiol antioxidants. Sulindac
sulfide increases cellular ROS level over time in SW480 and RKO cells. Sulindac sulfide decreases expression of Sp1, Sp3, Sp4, VEGF, bcl-2 and
survivin and these effects are completely or partially reversed by antioxidants DTT, GSH and NAC cotreatment. Sulindac sulfide decreases expression of
Bax in SW480 cells (reversible by antioxidants) but not in RKO cells. Sulindac sulfide also decreases expression of cyclin D1 and this is not reversible by
antioxidants. a Cells were treated with 100 μM sulindac sulfide and cellular ROS level was measured by flow cytometry as described under Materials
and Methods. Experiments were done in triplicate and results are expressed as fold of control (mean ± S.D.). Asterisk (*) indicates statistical difference
between control (DMSO) and treatment (P < 0.05). b, c Cells were treated with DMSO, sulindac sulfide alone or in combination with antioxidants as
indicated for 24 h. Antioxidants were pre-applied to cells for 45 min when used in combination with sulindac sulfide. Sp1, Sp3 and Sp4 cellular levels
were determined by Western blot analysis. d, e VEGF, bcl-2, Bax, survivin and cyclin D1 were determined by Western blot analysis as described under
Materials and Methods and β-actin was used as loading control
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effects of sulindac sulfide also involve induction of ROS
and the subsequent downregulation of miR-27a and in-
duction of the "Sp repressor" ZBTB10, and this pathway
has also been observed for other ROS inducers (Fig. 6d). It
has previously been reported that high Sp1/Sp3 binding to
the urokinase receptor predicted poor survival of colon
cancer patients [52] and high expression of Sp1 was asso-
ciated with an increased depth of invasion in another set
of colon cancer patients [53]. A previous study showed




Fig. 6 Effects of sulindac sulfide on miR-27a and ZBTB10 in colon cancer cells. a Sulindac sulfide decreases miR-27a promoter activity in SW480
and RKO cells. Cells were transfected with luciferase construct containing −638 bp promoter sequence of miR-27a gene (pMir27a-Luc). After 6 h,
cells were treated with DMSO, 75, 100 and 125 μM sulindac sulfide for 18 h and luciferase activity was determined as described under Materials
and Methods. b Sulindac sulfide decreases miR-27a transcript level in SW480 and RKO cells and this effect is reversed by antioxidant NAC. Cells
were treated with DMSO, 100 μM sulindac sulfide alone or in combination with 10 mM NAC for 24 h and cellular level of the miR-27a transcript
was determined by TaqMan PCR analysis as described under Materials and Methods. c Sulindac sulfide increases gene expression of ZBTB10 in
SW480 and RKO cells. Cells were treated with DMSO, 25, 50 and 75 μM sulindac sulfide for 24 h and ZBTB10 mRNA levels were determined by
real-time PCR analysis as described under Materials and Methods. All experiments were done in triplicate and results are expressed as fold of control
(mean ± S.D.). Asterisk (*) indicates statistical difference between control (DMSO) and treatment, and double-asterisk (**) indicates statistical difference
between single treatment and combination treatment (P < 0.05). d Effects of sulindac sulfide on the ROS-miR-27a-ZBTB10-Sp axis. Sulindac sulfide
induces ROS; downregulates miR-27a; upregulates ZBTB10; downregulates Sp proteins and Sp-dependent survival/proliferative, inflammatory and
angiogenic protein products; and induces growth inhibition and apoptosis
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[54]; however, a higher concentration (160 μM) was re-
quired, suggesting some specificity for cancer cell lines.
Thus, the advantage/effectiveness of sulindac in colon
cancer therapy may be due, in part, to the targeting of Sp
transcription factors and it is possible that other antican-
cer agents or drug combinations that act, in part, through
targeting Sp transcription factors may also be effective for
colon cancer therapy.
Abbreviations
COX: Cyclooxygenase; DMEM: Dulbecco’s modified Eagle’s medium;
DMSO: Dimethyl sulfoxide; DTT: Dithiothreitol; EGFR: Epidermal growth factor
receptor; GSH: Glutathione; miR-27a: microRNA-27a; NAC: N-acetylcysteine;
NSAIDs: Non-steroidal anti-inflammatory drugs; RNAi: RNA interference;
ROS: Reactive oxygen species; Sp: Specificity protein; VEGF: Vascular
endothelial growth factor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
XL carried out some of the experimental procedures, performed the
statistical analysis, reviewed initial draft of the manuscript. SSP carried out
some of the experimental procedures. SS conceived of the study,
participated in its design and coordination, wrote the initial draft of the
manuscript. All authors have read and approved the final manuscript.
Acknowledgements
Funding was provided by the National Institute of Environmental Health
Sciences (P30-ES023512), the Sid Kyle Endowment, and Texas AgriLife Research.
Author details
1Department of Veterinary Physiology & Pharmacology, Texas A&M
University, College Station, TX 77843-4466, USA. 2Oklahoma Medical Research
Foundation, 825 NE 13th St., Oklahoma City, OK 73104, USA.
Received: 7 July 2015 Accepted: 25 November 2015
References
1. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates,
and cancer. Lancet. 2009;373(9671):1301–9.
2. Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and
cancer. Prog Exp Tumor Res. 2003;37:1–24.
3. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort
study of long-term daily use of adult-strength aspirin and cancer incidence.
J Natl Cancer Inst. 2007;99(8):608–15.
4. Asano TK, McLeod RS. Nonsteroidal anti-inflammatory drugs and aspirin for
the prevention of colorectal adenomas and cancer: a systematic review. Dis
Colon Rectum. 2004;47(5):665–73.
5. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A
randomized trial of aspirin to prevent colorectal adenomas in patients with
previous colorectal cancer. N Engl J Med. 2003;348(10):883–90.
6. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A
randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med.
2003;348(10):891–9.
7. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, et al. Sulindac
causes regression of rectal polyps in familial adenomatous polyposis.
Gastroenterology. 1991;101(3):635–9.
8. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P,
et al. Treatment of colonic and rectal adenomas with sulindac in familial
adenomatous polyposis. N Engl J Med. 1993;328(18):1313–6.
9. Matsumoto T, Nakamura S, Esaki M, Yao T, Iida M. Effect of the non-steroidal
anti-inflammatory drug sulindac on colorectal adenomas of uncolectomized
familial adenomatous polyposis. J Gastroenterol Hepatol. 2006;21(1 Pt 2):251–7.
10. Scheper MA, Sauk JJ, Nikitakis NG. COX-independent antineoplastic effects
of sulindac in oral cancer are mediated by survivin down-regulation.
Anticancer Res. 2006;26(6B):4103–13.
11. Scheper MA, Nikitakis NG, Chaisuparat R, Montaner S, Sauk JJ. Sulindac
induces apoptosis and inhibits tumor growth in vivo in head and neck
squamous cell carcinoma. Neoplasia (New York, NY). 2007;9(3):192–9.
12. Scheper MA, Nikitakis NG, Sauk JJ. Survivin is a downstream target and
effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck
cancer. Int J Oral Maxillofac Surg. 2007;36(7):632–9.
13. Zhang T, Fields JZ, Ehrlich SM, Boman BM. The chemopreventive agent
sulindac attenuates expression of the antiapoptotic protein survivin in
colorectal carcinoma cells. J Pharmacol Exp Ther. 2004;308(2):434–7.
14. Seo SK, Lee HC, Woo SH, Jin HO, Yoo DH, Lee SJ, et al. Sulindac-derived
reactive oxygen species induce apoptosis of human multiple myeloma cells
via p38 mitogen activated protein kinase-induced mitochondrial
dysfunction. Apoptosis. 2007;12(1):195–209.
15. Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, Kuwada S, et al. Sulindac
metabolites induce caspase- and proteasome-dependent degradation of
beta-catenin protein in human colon cancer cells. Mol Cancer Ther. 2003;
2(9):885–92.
16. Li H, Liu L, David ML, Whitehead CM, Chen M, Fetter JR, et al. Pro-apoptotic
actions of exisulind and CP461 in SW480 colon tumor cells involve
beta-catenin and cyclin D1 down-regulation. Biochem Pharmacol.
2002;64(9):1325–36.
17. Han A, Song Z, Tong C, Hu D, Bi X, Augenlicht LH, et al. Sulindac
suppresses beta-catenin expression in human cancer cells. Eur J
Pharmacol. 2008;583(1):26–31.
18. Pangburn HA, Kraus H, Ahnen DJ, Rice PL. Sulindac metabolites inhibit
epidermal growth factor receptor activation and expression. Journal of
carcinogenesis. 2005;4:16.
19. Pangburn HA, Ahnen DJ, Rice PL. Sulindac metabolites induce proteosomal
and lysosomal degradation of the epidermal growth factor receptor. Cancer
Prev Res (Phila). 2010;3(4):560–72.
20. Pyriochou A, Tsigkos S, Vassilakopoulos T, Cottin T, Zhou Z, Gourzoulidou E,
et al. Anti-angiogenic properties of a sulindac analogue. Br J Pharmacol.
2007;152(8):1207–14.
21. Vaish V, Sanyal SN. Role of Sulindac and Celecoxib in the regulation of
angiogenesis during the early neoplasm of colon: exploring PI3-K/PTEN/Akt
pathway to the canonical Wnt/beta-catenin signaling. Biomed
Pharmacother. 2012;66(5):354–67.
22. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S. Betulinic acid inhibits
prostate cancer growth through inhibition of specificity protein
transcription factors. Cancer Res. 2007;67(6):2816–23.
23. Chadalapaka G, Jutooru I, Burghardt R, Safe S. Drugs that target specificity
proteins downregulate epidermal growth factor receptor in bladder cancer
cells. Molecular cancer research : MCR. 2010;8(5):739–50.
24. Abdelrahim M, Safe S. Cyclooxygenase-2 inhibitors decrease vascular
endothelial growth factor expression in colon cancer cells by enhanced
degradation of Sp1 and Sp4 proteins. Mol Pharmacol. 2005;68(2):317–29.
25. Pathi SS, Jutooru I, Chadalapaka G, Sreevalsan S, Anand S, Thatcher GR, et al.
GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a
reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway.
Molecular cancer research : MCR. 2011;9(2):195–202.
26. Jutooru I, Chadalapaka G, Lei P, Safe S. Inhibition of NFkappaB and
pancreatic cancer cell and tumor growth by curcumin is dependent on
specificity protein down-regulation. J Biol Chem. 2010;285(33):25332–44.
27. Safe S, Imanirad P, Sreevalsan S, Nair V, Jutooru I. Transcription factor Sp1,
also known as specificity protein 1 as a therapeutic target. Expert Opin Ther
Targets. 2014;18(7):759–69.
28. Nicolas M, Noe V, Jensen KB, Ciudad CJ. Cloning and characterization of the
5'-flanking region of the human transcription factor Sp1 gene. J Biol Chem.
2001;276(25):22126–32.
29. Tapias A, Monasterio P, Ciudad CJ, Noe V. Characterization of the 5'-flanking
region of the human transcription factor Sp3 gene. Biochim Biophys Acta.
2005;1730(2):126–36.
30. Finkenzeller G, Sparacio A, Technau A, Marme D, Siemeister G. Sp1
recognition sites in the proximal promoter of the human vascular
endothelial growth factor gene are essential for platelet-derived growth
factor-induced gene expression. Oncogene. 1997;15(6):669–76.
31. Zhu N, Gu L, Findley HW, Chen C, Dong JT, Yang L, et al. KLF5 Interacts with
p53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol
Chem. 2006;281(21):14711–8.
32. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. MicroRNA genes are
transcribed by RNA polymerase II. EMBO J. 2004;23(20):4051–60.
Li et al. BMC Cancer  (2015) 15:974 Page 10 of 11
33. Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, et al. Apoptosis
primarily accounts for the growth-inhibitory properties of sulindac
metabolites and involves a mechanism that is independent of
cyclooxygenase inhibition, cell cycle arrest, and p53 induction.
Cancer Res. 1997;57(12):2452–9.
34. Bock JM, Menon SG, Goswami PC, Sinclair LL, Bedford NS, Jackson RE, et al.
Differential activity of sulindac metabolites against squamous cell carcinoma
of the head and neck is mediated by p21waf1/cip1 induction and cell cycle
inhibition. Cancer Biol Ther. 2007;6(1):30–9.
35. Pathi S, Jutooru I, Chadalapaka G, Nair V, Lee SO, Safe S. Aspirin inhibits
colon cancer cell and tumor growth and downregulates specificity protein
(Sp) transcription factors. PLoS One. 2012;7(10):e48208.
36. Chintharlapalli S, Papineni S, Abdelrahim M, Abudayyeh A, Jutooru I,
Chadalapaka G, et al. Oncogenic microRNA-27a is a target for anticancer
agent methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate in colon
cancer cells. International journal of cancer Journal international du cancer.
2009;125(8):1965–74.
37. Pathi S, Li X, Safe S. Tolfenamic acid inhibits colon cancer cell and tumor
growth and induces degradation of specificity protein (Sp) transcription
factors. Mol Carcinog. 2014;53 Suppl 1:E53–61.
38. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S. Tolfenamic acid and
pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl
Cancer Inst. 2006;98(12):855–68.
39. Chadalapaka G, Jutooru I, Chintharlapalli S, Papineni S, Smith 3rd R, Li X,
et al. Curcumin decreases specificity protein expression in bladder cancer
cells. Cancer Res. 2008;68(13):5345–54.
40. Gandhy SU, Kim K, Larsen L, Rosengren RJ, Safe S. Curcumin and synthetic
analogs induce reactive oxygen species and decreases specificity
protein (Sp) transcription factors by targeting microRNAs. BMC Cancer.
2012;12:564.
41. Chadalapaka G, Jutooru I, Safe S. Celastrol decreases specificity proteins (Sp)
and fibroblast growth factor receptor-3 (FGFR3) in bladder cancer cells.
Carcinogenesis. 2012;33(4):886–94.
42. Jutooru I, Guthrie AS, Chadalapaka G, Pathi S, Kim K, Burghardt R, et al.
Mechanism of action of phenethylisothiocyanate and other reactive
oxygen species-inducing anticancer agents. Mol Cell Biol. 2014;34(13):
2382–95.
43. Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT, et al. Association between
expression of transcription factor Sp1 and increased vascular endothelial
growth factor expression, advanced stage, and poor survival in patients with
resected gastric cancer. Clin Cancer Res. 2004;10(12 Pt 1):4109–17.
44. Jiang NY, Woda BA, Banner BF, Whalen GF, Dresser KA, Lu D. Sp1,
a new biomarker that identifies a subset of aggressive pancreatic
ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev.
2008;17(7):1648–52.
45. Guan H, Cai J, Zhang N, Wu J, Yuan J, Li J, et al. Sp1 is upregulated in
human glioma, promotes MMP-2-mediated cell invasion and predicts poor
clinical outcome. Int J Cancer. 2012;130(3):593–601.
46. Ammendola R, Mesuraca M, Russo T, Cimino F. Sp1 DNA binding efficiency
is highly reduced in nuclear extracts from aged rat tissues. J Biol Chem.
1992;267(25):17944–8.
47. Adrian GS, Seto E, Fischbach KS, Rivera EV, Adrian EK, Herbert DC, et al. YY1
and Sp1 transcription factors bind the human transferrin gene in an age-
related manner. J Gerontol A Biol Sci Med Sci. 1996;51(1):B66–75.
48. Oh JE, Han JA, Hwang ES. Downregulation of transcription factor, Sp1, during
cellular senescence. Biochem Biophys Res Commun. 2007;353(1):86–91.
49. Iizaka M, Furukawa Y, Tsunoda T, Akashi H, Ogawa M, Nakamura Y.
Expression profile analysis of colon cancer cells in response to sulindac or
aspirin. Biochem Biophys Res Commun. 2002;292(2):498–512.
50. Pathi SS, Lei P, Sreevalsan S, Chadalapaka G, Jutooru I, Safe S.
Pharmacologic doses of ascorbic acid repress specificity protein (Sp)
transcription factors and Sp-regulated genes in colon cancer cells.
Nutr Cancer. 2011;63(7):1133–42.
51. Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S. The oncogenic microRNA-
27a targets genes that regulate specificity protein transcription factors and
the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 2007;
67(22):11001–11.
52. Maurer GD, Leupold JH, Schewe DM, Biller T, Kates RE, Hornung HM, et al.
Analysis of specific transcriptional regulators as early predictors of
independent prognostic relevance in resected colorectal cancer. Clin
Cancer Res. 2007;13(4):1123–32.
53. Wang F, Ma YL, Zhang P, Shen TY, Shi CZ, Yang YZ, et al. SP1 mediates the
link between methylation of the tumour suppressor miR-149 and outcome
in colorectal cancer. J Pathol. 2013;229(1):12–24.
54. Liou JY, Wu CC, Chen BR, Yen LB, Wu KK. Nonsteroidal anti-inflammatory
drugs induced endothelial apoptosis by perturbing peroxisome proliferator-
activated receptor-delta transcriptional pathway. Mol Pharmacol. 2008;74(5):
1399–406.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Li et al. BMC Cancer  (2015) 15:974 Page 11 of 11
